The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Open accessAbstract
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development and function of the nervous system through activation by neurotrophins. Gene fusions involving NTRK genes lead to transcription of chimeric Trk proteins with constitutively activated or overexpressed kinase function conferring oncogenic potential. These genetic abnormalities have recently emerged as targets for cancer therapy, because novel compounds have been developed that are selective inhibitors of the constitutively active rearranged proteins. Developments in this field are being aided by next generation sequencing methods as tools for unbiased gene fusions discovery. In this article, we review the role of NTRK gene fusions across several tumour histologies, and the promises and challenges of targeting such genetic alterations for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 1×
“The latter are specific ligands known as nerve growth factor (NGF) for TrkA, brain-derived growth factor (BDGF), and NT-4/5 for TrkB and NT3 for TrkC, respectively.(2) All three Trk receptors are structured with an extracellular domain for ligand binding, a transmembrane region and an intracellular domain with a kinas…”
BackgroundMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3
Lamballe, F., Klein, R., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90442-2 · Cited by 1,080
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Anchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C., Knezevich, S. R., Huntsman, D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L., Carneiro, F., MacPherson, N., Horsman, D., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 911
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 803
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
Knezevich, S. R., McFadden, D. E., Tao, W., Lim, J. F., & Sorensen, P. H. B. (1998) · Nature Genetics · doi:10.1038/ng0298-184 · Cited by 800
The emerging complexity of gene fusions in cancer
Mertens, F., Johansson, B., Fioretos, T., & Mitelman, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3947 · Cited by 682
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
A de novo mutation affecting human TrkB associated with severe obesity and developmental delay
Yeo, G. S. H., Connie Hung, C.-C., Rochford, J., Keogh, J., Gray, J., Sivaramakrishnan, S., O'Rahilly, S., & Farooqi, I. S. (2004) · Nature Neuroscience · doi:10.1038/nn1336 · Cited by 607
The integrated landscape of driver genomic alterations in glioblastoma
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2734 · Cited by 524
Trk receptor tyrosine kinases: A bridge between cancer and neural development
Nakagawara, A. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00530-4 · Cited by 495
Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 454
Doebele, R. C., Davis, L. E., Vaishnavi, A., Le, A. T., Estrada-Bernal, A., Keysar, S., Jimeno, A., Varella-Garcia, M., Aisner, D. L., Li, Y., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0443 · Cited by 388
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Russo, M., Misale, S., Wei, G., Siravegna, G., Crisafulli, G., Lazzari, L., Corti, G., Rospo, G., Novara, L., Mussolin, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0940 · Cited by 308
Self-citationHigh frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.
Bongarzone, I., Pierotti, M. A., Monzini, N., Mondellini, P., Manenti, G., Donghi, R., Pilotti, S., Grieco, M., Santoro, M., & Fusco, A. (1989) · PubMed · Cited by 287
Sartore-Bianchi, A., Ardini, E., Bosotti, R., Amatu, A., Valtorta, E., Somaschini, A., Raddrizzani, L., Palmeri, L., Banfi, P., Bonazzina, E., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv306 · Cited by 245
Self-citationIdentification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers
Ricarte-Filho, J. C., Li, S., Garcia-Rendueles, M. E. R., Montero-Conde, C., Voza, F., Knauf, J. A., Heguy, A., Viale, A., Bogdanova, T., Thomas, G. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69766 · Cited by 241
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Farago, A. F., Le, L. P., Zheng, Z., Muzikansky, A., Drilon, A., Patel, M., Bauer, T. M., Liu, S. V., Ou, S.-H. I., Jackman, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000473485.38553.f0 · Cited by 229
Tomasson, M. H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., Ries, R. E., Lubman, O., Fremont, D. H., McLellan, M. D., et al. (2008) · Blood · doi:10.1182/blood-2007-09-113027 · Cited by 227
Tacconelli, A., Farina, A. R., Cappabianca, L., DeSantis, G., Tessitore, A., Vetuschi, A., Sferra, R., Rucci, N., Argenti, B., Screpanti, I., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.011 · Cited by 208
Rearrangements of NTRK1 gene in papillary thyroid carcinoma
Greco, A., Miranda, C., & Pierotti, M. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.009 · Cited by 190
Bongarzone, I., Vigneri, P. G., Mariani, L., Collini, P., Pilotti, S., & Pierotti, M. A. (1998) · PubMed · Cited by 178
Abrams, J., Conley, B., Mooney, M., Zwiebel, J., Chen, A., Welch, J. J., Takebe, N., Malik, S., McShane, L., Korn, E., et al. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.71 · Cited by 159
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
Rolfo, C. D., Ruiz, R., Giovannetti, E., Bazo, I. G., Russo, A. D., Passiglia, F., Giallombardo, M., Peeters, M., & Raez, L. E. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1096344 · Cited by 157
Mardy, S., Miura, Y., Endo, F., Matsuda, I., Sztriha, L., Frossard, P., Moosa, A., Ismail, E. A. R., Macaya, A., Andria, G., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302422 · Cited by 157
The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition
Bertrand, T., Kothe, M., Liu, J., Dupuy, A., Rak, A., Berne, P., Davis, S. H., Gladysheva, T. B., Valtre, C., Crenne, J. Y., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.08.002 · Cited by 134
Patwardhan, P. P., Ivy, K. S., Musi, E., de Stanchina, E., & Schwartz, G. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6547 · Cited by 121
Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2)
Nakagawara, A., Liu, X.-G., Ikegaki, N., White, P. S., Yamashiro, D. J., Nycum, L. M., Biegel, J. A., & Brodeur, G. M. (1995) · Genomics · doi:10.1016/0888-7543(95)80055-q · Cited by 109
Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma
Créancier, L., Vandenberghe, I., Gomes, B., Dejean, C., Blanchet, J.-C., Meilleroux, J., Guimbaud, R., Sèlves, J., & Kruczynski, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.013 · Cited by 93
Shah, N., Lankerovich, M., Lee, H., Yoon, J., Schroeder, B., & Foltz, G. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-818 · Cited by 86
Smith, B. D., Kaufman, M. D., Leary, C. B., Turner, B. A., Wise, S., Ahn, Y. M., Booth, R. J., Caldwell, T. M., Ensinger, C. L., Hood, M. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1105 · Cited by 81
TrkB inhibition as a therapeutic target for CNS-related disorders
Boulle, F., Kenis, G., Cazorla, M., Hamon, M., Steinbusch, H. W. M., Lanfumey, L., & van den Hove, D. L. A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.002 · Cited by 80
Indo, Y., Mardy, S., Miura, Y., Moosa, A., Ismail, E. A. R., Toscano, E., Andria, G., Pavone, V., Brown, D., Brooks, A., et al. (2001) · Human Mutation · doi:10.1002/humu.1192 · Cited by 67
Valent, A., Danglot, G., & Bernheim, A. (1997) · European Journal of Human Genetics · doi:10.1159/000484742 · Cited by 64
Delvincourt, C., Patey, M., Flament, J. B., Suarez, H. G., Larbre, H., Jc, J., & Delisle, M. J. (1996) · Clinical Biochemistry · doi:10.1016/0009-9120(96)00006-9 · Cited by 39
Rea, I. M., Gillen, S., & Clarke, E. (1997) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1600370 · Cited by 30
Cited by
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citationNTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Self-citationNew Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Metadata
- Authors
- Amatu, A., Sartore-Bianchi, A., & Siena, S.
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2016
- Volume
- 1
- Issue
- 2
- Pages
- e000023
- ISSN
- 2059-7029 (ISSN-L)
- OpenAlex
- W2335155752
- Cited by
- 601
- References
- 44
- FWCI
- 38.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.